CNR2 and metabolic dysfunction-associated steatotic liver disease: Treatment with JWH-133, a CB2 agonist, exacerbated liver inflammation and the development of fatty liver in HFD-fed wild-type mice, suggesting a potential association between CB2 and an increased risk of developing NAFLD.